Durata Therapeutics CEO Acquires $45,690 in Stock (DRTX)
Durata Therapeutics (NASDAQ:DRTX) CEO Paul R. Edick bought 3,000 shares of the stock on the open market in a transaction dated Thursday, June 12th. The shares were purchased at an average cost of $15.23 per share, with a total value of $45,690.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $21.00 to $24.00 in a research note on Tuesday, May 27th. They now have a “buy” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Durata Therapeutics from $19.00 to $23.00 in a research note on Tuesday, May 27th. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Durata Therapeutics from $14.00 to $15.00 in a research note on Tuesday, May 27th. They now have a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Durata Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $19.38.
Durata Therapeutics (NASDAQ:DRTX) traded up 1.50% on Friday, hitting $15.55. 269,999 shares of the company’s stock traded hands. Durata Therapeutics has a 52 week low of $6.70 and a 52 week high of $17.20. The stock’s 50-day moving average is $15.15 and its 200-day moving average is $13.3. The company’s market cap is $414.3 million.
Durata Therapeutics (NASDAQ:DRTX) last released its earnings data on Thursday, May 8th. The company reported ($0.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.64) by $0.02. Analysts expect that Durata Therapeutics will post $-2.39 EPS for the current fiscal year.
Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.